The World Health Organization (WHO) has expressed deep dismay following the raid on Kamal Adwan Hospital, which has rendered the last major health facility in North Gaza non-operational. This attack…
WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has entered a service agreement with Sino Biopharm, an innovative R&D-driven pharmaceutical group in China, to develop a…
BeiGene a global oncology Chemotherapy company that plans to rebrand itself as BeOne Medicines Ltd., has achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of…
ICON plc a leading global healthcare intelligence and clinical research organization, has received multiple prestigious awards in the second half of 2024, further solidifying its position as a top performer…
Argenx SE a global immunology company dedicated to improving the lives of people affected by severe autoimmune diseases, has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has…
Colorectal Cancer Breakthrough: Bristol Myers Squibb Secures EC Approval for Opdivo + Yervoy in MSI-High mCRC Bristol Myers Squibb has announced that the Colorectal Cancer European Commission (EC) has approved…
Bristol Myers Squibb has announced positive results from arthritis two pivotal Phase 3 trials, POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), which evaluated the efficacy and safety of Sotyktu (deucravacitinib)…
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection for subcutaneous use. This innovative combination product…
In a significant victory for patient safety, the judge presiding over Eli Lilly’s case before the International Trade Commission (ITC) ruled that U.S. Customs and Border Protection should block the…
Aetna , a CVS Health® company , has enhanced the functionality of its Aetna Health℠ app to offer Spanish language support for all eligible health plan members, regardless of their…
Regeneron Pharmaceuticals has announced positive Phase 2 results for two innovative monoclonal antibodies targeting distinct domains of Factor XI. REGN7508, designed to maximize anticoagulant activity while minimizing bleeding risk, targets…
Merck, a leading science and technology company, announced plans to invest over €70 million in constructing a new Advanced Materials Development Center (AMDC) at its Shizuoka site in Japan. This…